E.C.M. RES.:
ONDA BLU:LA PREVENZIONEDEL TUMOREDEL COLON RETTO
LA SECONDA ONDA:“IN(form)AZIONE”
06 June 2026
Università degli Studi (Aula del '400) - PAVIA
TYPOLOGY
RES
FREE
DATE
06/06/2026
END DATE
06/06/2026
Scientific rationale
The prevalence of tumors is generally increased in relation to the ageing of the population and without the adoption of decisive actions, it is estimated that the lives lost for this disease will increase up to 24% by 2035.
Il tumore del colon-retto è una delle neoplasie più diffuse al mondo, con un’incidenza e una mortalità significative anche nella popolazione italiana (solo nel 2023 sono stati diagnosticati 50.500 nuovi casi) ma il dato più preoccupante è l’aumento mondiale di incidenza nei più giovani (1 su 10 in soggetti <50aa ed anche giovanissimi).
This evidences the importance of reflecting on this disease also for age groups traditionally considered at a low risk for which in this historical era in which we witness a daily technological evolution and therefore diagnostic/operative, the fight against tumors, and in particular that of the rectum colon, represents as never before a challenge for all.
Early prevention/diagnosis plays a decisive role and falls within the Essential Levels of Assistance (LEA), essential performance that must be guaranteed to all citizens, but a lot must be worked especially to spread culture and awareness about the adoption of healthy lifestyles and the reduction of individual risk factors.
Cultural and social reflections and challenges arise as conditions such as obesity, overweight, alcohol and smoke consumption are recognised as risk determinants for other modifiable. For this reason, it is essential to promote awareness-raising and empowerment programmes aimed at all citizens and especially young people.
At the same time, it is also important to know its family history since about 20% of the colon-rect cancer cases in subjects under the age of 50 have a genetic familiarity or predisposition, which increases the risk.
Protagonist is therefore always the citizen as the recipient of adequate information process and whose satisfaction of need for health-care implies, however, a synergistic collaboration between various health professionals who interact by applying specific management standards for each individual competence for the offer of a prevention path that can be effective and supportive.
The project "IN(form)AZIONE", which aims to support locally the National Campaign for the Prevention of Rect Colon Tumour, in addition to the scientific session to which citizens who wished can participate, provides an innovative session dedicated to them.
CONTRIBUTION

WITH THE PATROCINIUS OF

START
06 June 2026
END OF COURSE
06 June 2026
TYPOLOGY
RES
LOCATION
Università degli Studi (Aula del '400) - Pavia
PARTICIPANTS
100
TARGETS
MEDICI CHIRURGHI - PROFESSIONAL INFERMIERS - DIETISTS
REFERENCE SPIPLINES:
MEDICINAL PRODUCTS
ECM ID
752 - 482989
N. CREDITS RES
6
REGISTERING QUOTA
Free
E-MAIL
info@studio-congressi.com
Studio Congressi s.r.l.
VAT: 01975530187
Reg. Companies of Pv: 01975530187
R.E.A.: 235792
Social Capital: € 260.000,00
VAT: 01975530187
Reg. Companies of Pv: 01975530187
R.E.A.: 235792
Social Capital: € 260.000,00
Studio Congressi s.r.l. and Med Tech Science s.r.l.
Avenue of Liberty, 17 | 27100 Pavia (PV)
📞 +39.0382.21424 | +39.351.8055151
info@studio-congressi.com
medtechscience2@gmail.com
Code Recipient SDI BA6ET11
Med Tech Science Ltd.
VAT No: 02080160183
Reg. Pv: 02080160183
R.E.A.: 244029
Social Capital: € 100,000,00
Studio Congressi s.r.l. and Med Tech Science s.r.l.
Avenue of Liberty, 17 | 27100 Pavia (PV)
📞 +39.0382.21424 | +39.351.8055151
info@studio-congressi.com
medtechscience2@gmail.com
Code Recipient SDI BA6ET11
Studio Congressi s.r.l.
VAT: 01975530187
Reg. Companies of Pv: 01975530187
R.E.A.: 235792
Social Capital: € 260.000,00
Med Tech Science Ltd.
VAT No: 02080160183
Reg. Pv: 02080160183
R.E.A.: 244029
Social Capital: € 100,000,00
